Recent Updates
Recently added Catalysts

Malignant Melanoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$3.9Buniverse median $1.20B
Allocated capital$657M$3.9B competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank183/299crowding rank 194

Malignant Melanoma is uncontested. Iovance Biotherapeutics (IOVA) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Lifileucel in phase 2.

There is no public comparable to price it against. IOVA spreads its $3.9B market cap across 6 indications, so $657M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$657M of allocated capital sits in Malignant Melanoma, ranking it 183rd of 299 indications by the money committed to it.

Companies developing drugs for Malignant Melanoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
IOVAIovance BiotherapeuticsLifileucelPhase 21$3.9BNo6 23 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Malignant Melanoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Malignant Melanoma has one competitor and a median of $3.9B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Unresectable Melanoma1 company · $657M · median $3.9BUncontestedAdvanced Cutaneous Melanoma1 company · $634M · median $1.3BUncontestedCastration-Resistant Metastatic Prostate Cancer1 company · $613M · median $1.2BUncontestedRelapsed or Refractory Non-Hodgkin's Lymphoma1 company · $601M · median $601MUncontestedNon-Muscle Invasive Bladder Cancer (NMIBC)1 company · $723M · median $8.7BUncontestedRefractory Non-Hodgkin's Lymphoma1 company · $723M · median $8.7BUncontestedHPV-Related Carcinoma1 company · $723M · median $8.7BUncontestedMyelodysplastic Syndromes2 companies · $572M · median $1.5BConcentrated bet

Malignant Melanoma pipeline questions

Which biotech companies are developing drugs for Malignant Melanoma?

Iovance Biotherapeutics (IOVA, Lifileucel, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Malignant Melanoma.

How advanced is the Malignant Melanoma pipeline?

Of the 1 clinical-stage programme in Malignant Melanoma, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Malignant Melanoma?

No. IOVA is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Malignant Melanoma, which is why the indication is classified as uncontested.

When is the next Malignant Melanoma catalyst?

The next dated catalyst in Malignant Melanoma is IOVA on 23 Oct 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map